Table 1. Correlation between the clinicopathologic variables and HIF-2α in HCC.
| Variables | Total | HIF-2α expression | P value Chi-square | |
| Low expression | High expression | |||
| Age(years) | ||||
| ≤50 | 74(53.2%) | 44(59.5%) | 30(40.5%) | 0.054 |
| >50 | 65(48.6%) | 28(43.1%) | 37(56.9%) | |
| Gender | ||||
| male | 116(83.5%) | 58(50%) | 58(50%) | 0.341 |
| female | 23(16.5%) | 14(60.9%) | 9(39.1%) | |
| TMN stage | ||||
| I | 107(77.0%) | 59(55.1%) | 48(44.9%) | 0.108 |
| II | 9(6.5%) | 4(44.4%) | 5(55.6%) | |
| III | 5(3.6%) | 0(0%) | 5(100%) | |
| IV | 18(12.9%) | 9(50%) | 9(50%) | |
| Lymph node metastasis | ||||
| no | 122(87.8%) | 64(52.5%) | 58(47.5%) | 0.676 |
| yes | 17(12.2%) | 8(47.1%) | 9(52.9%) | |
| Tumor size, cm | ||||
| ≤5 cm | 85(61.2%) | 54(63.5%) | 31(36.5%) | 0.001** |
| >5 cm | 54(38.8%) | 18(33.3%) | 36(66.7%) | |
| Tumor number | ||||
| solitary | 123(88.5%) | 68(55.3%) | 55(44.7%) | 0.021* |
| multiple | 16(11.5%) | 4(25%) | 12(75%) | |
| Tumor recurrence | ||||
| no | 128(92.1%) | 66(51.6%) | 62(48.4%) | 0.849 |
| yes | 11(7.9%) | 6(54.5%) | 5(45.5%) | |
| Metastasis | ||||
| no | 137(98.6%) | 70(51.1%) | 67(48.9%) | 0.169 |
| yes | 2(1.4%) | 2(100%) | 0(0%) | |
| ALT | ||||
| normal | 57(41%) | 42(73.7%) | 15(26.3%) | <0.001*** |
| increase | 82(59%) | 30(36.6%) | 52(63.4%) | |
| Total bilirubin | ||||
| normal | 88(63.3%) | 47(53.1%) | 41(46.6%) | 0.618 |
| increase | 51(36.7%) | 25(49%) | 26(51%) | |
| AFP | ||||
| <400 | 100(71.9%) | 52(52.0%) | 48(48%) | 0.939 |
| ≥400 | 39(28.1%) | 20(51.3%) | 19(48.7%) | |
| HBsAg | ||||
| negative | 36(25.9%) | 20(55.6%) | 16(44.4%) | 0.600 |
| positive | 103(74.1%) | 52(50.5%) | 51(49.5%) | |
| Albumin | ||||
| normal | 77(55.4%) | 43(55.8%) | 34(44.2%) | 0.287 |
| decrease | 62(44.6%) | 29(46.8%) | 33(53.2%) | |
TNM, tumor-node-metastasis; ALT, Alanine aminotransferase; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein